HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.

AbstractBACKGROUND:
Lymphoid neoplasm with 18q21.3/BCL2 and 8q24/MYC translocation to immunoglobulin (IG) genes as dual-hit lymphoma/leukemia is very rare and known to have a poor clinical outcome.
DESIGN AND METHODS:
To clarify the clinicopathological characteristics of this malignancy, we analyzed 27 cases of cytogenetically proven dual-hit lymphoma/leukemia.
RESULTS:
Dual-hit lymphoma/leukemia was diagnosed at presentation in 22 cases and at relapse or disease progression in 5 cases. At the time of diagnosis of dual-hit lymphoma/leukemia, extranodal involvement was found in 25 cases (93%) and central nervous system involvement occurred in 15 cases (56%). The median survival and 1-year survival rate of the 27 cases were only 6 months and 22%, respectively, after diagnosis of the dual-hit lymphoma/leukemia. Seven cases of triple-hit lymphoma/leukemia (dual-hit lymphoma/leukemia with 3q27/BCL6 translocation) were included; the median survival of these patients was only 4 months from the diagnosis of the dual-hit lymphoma/leukemia. The duration of survival of the patients with a triple-hit malignancy was shorter than that of the other 20 cases of dual-hit lymphoma/leukemia (p=0.02). The translocation partner of MYC subdivided the dual-hit cases into two groups; 14 cases of IGH and 13 cases of IGK/L. The MIB-1 index was investigated in 14 cases with aggressive B-cell lymphoma, and was higher in the group with MYC-IGH translocation (n=7) than in the MYC-IGK/L group (n=7) (p=0.02). Overall survival was not different between the MYC-IGH translocation group (n=14) and the MYC-IGK or MYC-IGL translocation group (n=13).
CONCLUSIONS:
Dual-hit lymphoma/leukemia is a rare but distinct mature B-cell neoplasm with an extremely poor prognosis characterized by frequent extranodal involvement and central nervous system progression with either of the translocation partners of MYC.
AuthorsNaoto Tomita, Mami Tokunaka, Naoya Nakamura, Kengo Takeuchi, Junki Koike, Shigeki Motomura, Ko Miyamoto, Ako Kikuchi, Rie Hyo, Yoshihiro Yakushijin, Yasufumi Masaki, Soichiro Fujii, Takamasa Hayashi, Yoshiaki Ishigatsubo, Ikuo Miura
JournalHaematologica (Haematologica) Vol. 94 Issue 7 Pg. 935-43 (Jul 2009) ISSN: 1592-8721 [Electronic] Italy
PMID19535347 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged
  • Chromosomes (ultrastructure)
  • Female
  • Genes, bcl-2
  • Genes, myc
  • Humans
  • Leukemia (diagnosis, genetics)
  • Lymphoma (diagnosis, genetics)
  • Male
  • Middle Aged
  • Prognosis
  • Time Factors
  • Translocation, Genetic
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: